GlassScriptPhysician profile
Donald Messersmith
NPI 1538235338
$1,364.82
in general payments reported to CMS, 2019-2025
17 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2021: $208 · 2022: $124 · 2023: $315 · 2024: $149 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $238.39 | 2019-2023 | Xarelto |
| Pfizer INC. | $184.35 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $183.56 | 2019-2025 | |
| Amgen INC. | $148.08 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $146.90 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $75.90 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $70.72 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.23 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.02 | 2023 | Jardiance |
| Amarin Pharma, INC. | $32.75 | 2019 | |
| Abiomed | $30.59 | 2019-2025 | |
| Astellas Pharma US INC | $30.00 | 2019 | |
| Cvrx, INC. | $24.63 | 2025 | Barostim Neo System |
| Baxter Healthcare | $24.46 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Daiichi Sankyo INC. | $23.78 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braemar Manufacturing, LLC | $23.60 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.86 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Messersmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.